News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Evotec AG (EVTG.F) to Terminate Registration of its Securities Under Section 12(g) and Terminate its Reporting Obligations Under Sections 13(a) and 15(d) of the U.S. Securities Exchange Act of 1934


12/30/2010 11:23:36 AM

HAMBURG, GERMANY--(Marketwire - December 30, 2010) -

Evotec AG / Evotec to terminate registration of its securities under Section 12(g) and terminate its reporting obligations under Sections 13(a) and 15(d) of the U.S. Securities Exchange Act of 1934 Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) (OTCBB: EVTCY) announced today that, pursuant to the decision of Evotec's Executive Board on 5 November 2009 to delist Evotec's American Depositary Shares (ADSs) from the NASDAQ stock market and, as soon thereafter as Evotec became eligible, to deregister and terminate its reporting obligations under the U.S. Securities Exchange Act of 1934 (Exchange Act) for its ADSs and its ordinary shares underlying the ADSs, it will file a Form 15F with the Securities and Exchange Commission (SEC) to deregister and terminate such reporting obligations. The deregistration and termination of reporting obligations is expected to take effect in March 2011.

In addition, on 20 November 2009 Evotec filed a Form 25 with the SEC, pursuant to which the last day of trading of Evotec's ADSs on the NASDAQ stock market was 30 November 2009. Following the delisting, Evotec has maintained its ADS facility, and its ADSs are traded on the over-the-counter (OTC) market in the U.S. Evotec's ordinary shares will continue to trade on the Frankfurt Stock Exchange. This notice is being published pursuant to the requirements of Rule 12h-6(h) of the Exchange Act in order to alert U.S. investors who have purchased Evotec's ADSs about Evotec's intended exit from the Exchange Act registration and reporting system.

Upon the filing of Form 15F, Evotec's reporting obligations under the Exchange Act are immediately suspended and the deregistration will become effective 90 days later unless the Form 15F is withdrawn by Evotec before then or the SEC delays the deregistration process. Evotec reserves the right to withdraw the Form 15F for any reason prior to its effectiveness.

Evotec will continue to publish its Annual Report and other documents and communications in accordance with Exchange Act Rule 12g3-2(b) in English on its website at www.evotec.com.






Pdf of Press Release: http://hugin.info/131215/R/1476027/412127.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1476027]


Contact:
Evotec AG
Christian von Spiegel, General Counsel
Phone: + 49 40 560 81 246
E-Mail: Email Contact


Read at BioSpace.com


comments powered by Disqus
Evotec AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES